RCEL
AVITA Medical, Inc.
RCEL lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
RCEL Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Under pressure | |
| Unavailable |
RCEL's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
RCEL PE Valuation
RCEL has no meaningful PE right now: it lost money over the past year.
RCEL Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect RCEL's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
RCEL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.17 | +$0.64 |
| Q2 2026 | -$1.43 | +$0.54 |
| Q1 2026 | -$1.56 | +$0.63 |
| Q4 2025 | -$1.74 | +$0.65 |
| Q3 2025 | -$1.81 | +$0.42 |
| Q2 2025 | -$1.97 | -$0.02 |
| Q1 2025 | -$2.19 | -$0.43 |
| Q4 2024 | -$2.39 | -$0.99 |
RCEL is still losing money, but far less than before: $1.17 per share over the past year, against $2.39 at its worst in late 2024.
RCEL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $26.1M | +53% |
| Q2 2026 | $21.7M | +18% |
| Q1 2026 | $19.3M | +4% |
| Q4 2025 | $17.6M | -4.3% |
| Q3 2025 | $17.1M | -13% |
| Q2 2025 | $18.4M | +21% |
| Q1 2025 | $18.5M | +67% |
| Q4 2024 | $18.4M | +30% |
RCEL's revenue is growing: $26M last quarter, up 53% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -10% | +44 points |
| Q2 2026 | -32% | +29 points |
| Q1 2026 | -46% | +18 points |
| Q4 2025 | -59% | -5 points |
| Q3 2025 | -54% | +17 points |
| Q2 2025 | -61% | +42 points |
| Q1 2025 | -64% | +91 points |
| Q4 2024 | -54% | +32 points |
RCEL's operating margin was −10% last quarter, up 44 points from the same quarter a year ago, near the top of its range since 2019.
RCEL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$821K | +$5.3M |
| Q2 2026 | -$3.6M | +$7.1M |
| Q1 2026 | -$10.1M | +$439K |
| Q4 2025 | -$4.8M | +$4.9M |
| Q3 2025 | -$6.2M | +$4.8M |
| Q2 2025 | -$10.8M | +$4.7M |
| Q1 2025 | -$10.5M | +$11.5M |
| Q4 2024 | -$9.7M | +$1.5M |
RCEL has burned cash in almost every quarter: −$19M over the past year, against −$37M the year before.
RCEL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +116K shares |
| 1 year | +8.7% | +2.5M shares |
| 3 years | +22% | +5.5M shares |
| 5 years | +24% | +6M shares |
| Available history | +65% | +12.1M shares |
RCEL has 31M diluted shares, up 8.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2020 | — |
| Q4 2019 | — |
| Q3 2019 | — |
RCEL Net Leverage
RCEL's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
RCEL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 79.9 | Overbought |
| Stochastic | 86.4 | Overbought |
RCEL's weekly RSI is 80 (overbought) and its Stochastic is 86 (overbought).
RCEL PE vs Healthcare Sector
RCEL has no meaningful PE right now: it lost money over the past year.
RCEL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $14.4 | 13% above |
| 20 week MA | $10.3 | 57% above |
| 50 week MA | $6.62 | 145% above |
| 100 week MA | $6.74 | 140% above |
| 200 week MA | $9.73 | 66% above |
RCEL has climbed back above all five of its weekly moving averages, and it's now 66% above its 200-week average.
RCEL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $44.7 | $19.0 | -58% |
| 2021 | $19.0 | $12.6 | -34% |
| 2022 | $12.6 | $6.76 | -46% |
| 2023 | $6.76 | $13.7 | +103% |
| 2024 | $13.7 | $13.5 | -1.7% |
| 2025 | $13.5 | $3.44 | -74% |
| 2026 YTD | $3.44 | $16.2 | +371% |
RCEL's yearly returns have swung widely, from +103% in 2023 to −74% in 2025. It's up 371% so far in 2026.